



ADULT Medication Monograph




# CLOTRIMAZOLE

This document should be read in conjunction with this [DISCLAIMER](#)

[Antimicrobial Restriction – Unrestricted \(Topical\)](#)

<b>Presentation</b>	Cream: 10% Solution: 1% Vaginal cream: 1% (6 day course) Pessary: 100mg (6 day course) Pessary: 500mg (1 day course)
<b>Dose</b>	<b><u>Acute and recurrent Candidiasis</u></b> <b>1% Vaginal Cream:</b> 1 applicatorful intravaginally, once daily at bedtime for 6 nights  <b>10% Vaginal Cream:</b> 1 applicatorful intravaginally, as a single dose at night  <b>100mg Vaginal Pessary:</b> 1 pessary intravaginally, once daily at bedtime for 6 nights  <b>500mg Vaginal Pessary:</b> 1 pessary intravaginally, at bedtime once only  <b>Recurrent Candidiasis relapse prevention</b> Clotrimazole 500mg pessary intravaginally, weekly  <b><u>Pregnancy</u></b> Topical treatment must be used for 12-14 days in pregnancy because of lower response rates and more frequent relapse.
<b>Administration</b>	In the third trimester of pregnancy extreme caution should be observed when using applicators due to risk of rupturing the membranes. KEMH Pharmaceutical & Medicines Management Guideline: <a href="#">Medication Administration</a>

<b>Pregnancy</b>	<p><b>1<sup>st</sup> Trimester:</b> Safe to use</p> <p><b>2<sup>nd</sup> Trimester:</b> Safe to use</p> <p><b>3<sup>rd</sup> Trimester:</b> Safe to use</p> <p>Use in pregnant patients: Digital insertion of vaginal treatment is preferable to the use of applicator in late pregnancy</p>
<b>Breastfeeding</b>	Safe to use
<b>Other clinical guidelines</b>	<p>WNHS Policy: <a href="#">Antimicrobial Stewardship</a></p> <p>KEMH Pharmaceutical &amp; Medicines Management Guideline: <a href="#">Medication Administration</a></p> <p>KEMH Pharmaceutical &amp; Medicines Management Guideline: <a href="#">Prescribing by Eligible Private Practicing Midwives with a Scheduled Medicines Endorsement</a></p> <p>KEMH Clinical Guideline: O&amp;G: <a href="#">Sexually Transmitted Infections (STI)</a></p> <p>KEMH Clinical Guideline: O&amp;G: <a href="#">Vaginal Infections: Treatment for Candidiasis</a></p> <p>KEMH Clinical Guideline: O&amp;G: <a href="#">Antenatal Care: Minor Symptoms or Disorders in Pregnancy</a></p>
<b>References</b>	<p>Australian Medicines Handbook. Clotrimazole. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2019 [cited 2019 Mar 28]. Available from: <a href="https://amhonline.amh.net.au/">https://amhonline.amh.net.au/</a></p> <p>Therapeutic Guidelines. Candidal vulvovaginitis in women. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines Anitobitic V15; [cited 2019 Mar 28]. Available from: <a href="https://tgldcdp.tg.org.au">https://tgldcdp.tg.org.au</a></p> <p>MIMS Australia. Clotrimazole. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2019 [cited 2019 Mar 28]. Available from: <a href="https://www.mimsonline.com.au">https://www.mimsonline.com.au</a></p> <p>The Royal Women's Hospital. Clotrimazole. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2019 [cited 2019 Mar 28]. Available from: <a href="https://thewomenspbmg.org.au/">https://thewomenspbmg.org.au/</a></p> <p>Sexual Health and Blood-borne Virus Program. Non-notifiable infections: Candidiases. Silver book - guidelines for managing sexually transmitted infections and blood-borne viruses [Internet]. Perth (WA): Government of Western Australia Department of Health; 2015 [cited 2019 Mar 28]. Available from: <a href="https://ww2.health.wa.gov.au/Silver-book/Non-notifiable-infections/Candidiasis">https://ww2.health.wa.gov.au/Silver-book/Non-notifiable-infections/Candidiasis</a></p>

Keywords:	Clotrimazole, candidiasis, trichomoniasis, Canesten		
Publishing:	<input checked="" type="checkbox"/> Intranet <input checked="" type="checkbox"/> Internet		
Document owner:	Chief Pharmacist		
Author / Reviewer:	Pharmacy Department		
Date first issued:	January 2015	Version:	3.0
Last reviewed:	March 2019	Next review date:	March 2022
Endorsed by:	Medicines and Therapeutics Committee	Date:	Mar 2019
Standards Applicable:	NSQHS Standards: 1  Governance, 3  Infection Control, 4  Medication Safety		
<p><b>Printed or personally saved electronic copies of this document are considered uncontrolled.</b></p> <p><b>Access the current version from the WNHS website.</b></p> <p><b>For any enquiries relating to this guideline, please email <a href="mailto:KEMH.PharmacyAdmin@health.wa.gov.au">KEMH.PharmacyAdmin@health.wa.gov.au</a></b></p>			

© Department of Health Western Australia 2019